My laboratory research program focuses on the treatment of patients with lymphomas, including Hodgkin and non-Hodgkin lymphoma.  I have played a major role in clinical trials for the application of targeted therapeutic agents in lymphoma, with one recent study demonstrating efficacy of the mTOR inhibitor temsirolimus in specific forms of non-mantle cell non-Hodgkin’s lymphoma.  We are also interested in hepatosplenic gamma-delta T-cell lymphoma, a rare peripheral T cell lymphoma that does not respond to standard antracycline-containing chemotherapy: our work is helping to define the clinical features of patients with better versus poorer clinical prognosis.  One of our important goals in clinical research is to develop effective new combination therapies in conjunction with the creation of efficient scoring systems for patient prognosis, to maximize the response of each patient to treatment.